Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) Equity Average (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Equity Average for 8 consecutive years, with $164.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average rose 122.97% to $164.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $164.6 million, a 122.97% increase, with the full-year FY2024 number at $78.8 million, down 40.18% from a year prior.
  • Equity Average was $164.6 million for Q3 2025 at Whitehawk Therapeutics, down from $196.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $196.9 million in Q2 2025 to a low of -$19.2 million in Q1 2021.
  • A 5-year average of $108.7 million and a median of $124.8 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: tumbled 78.59% in 2021, then skyrocketed 780.43% in 2022.
  • Whitehawk Therapeutics' Equity Average stood at $143.7 million in 2021, then rose by 13.98% to $163.7 million in 2022, then tumbled by 31.79% to $111.7 million in 2023, then plummeted by 45.68% to $60.7 million in 2024, then surged by 171.32% to $164.6 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Equity Average are $164.6 million (Q3 2025), $196.9 million (Q2 2025), and $137.1 million (Q1 2025).